Ultra Market Research | United States (U.S.) Pharmaceutical Contract development and manufacturing organizations (CDMO) Market
United States (U.S.) Pharmaceutical Contract development and manufacturing organizations (CDMO) Market
Report ID : 620
Category : Pharmaceuticals,Biotechnology
No Of Pages : 140
Published on: August 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United States (U.S.) Pharmaceutical Contract development and manufacturing organizations (CDMO) Market Growing at a CAGR of XX% from 2024 to 2033, the U.S. pharmaceutical CDMO market was valued at US$ XX billion in 2023 and is projected to reach US$ XX billion by 2033. Through services ranging from research and development to manufacturing, formulation to finishing processes, CDMOs play a crucial role in assisting pharmaceutical firms throughout the whole lifecycle of medicinal product development. Industry consolidation efforts that have propelled a dynamic landscape of mergers and acquisitions (M&A) have propelled the amazing expansion of the CDMO sector over the last ten years. Global CDMOs with several awards, such as Pfizer CentreOne, use their parent corporations' vast scientific and technological know-how to produce pharmaceuticals and biotech products. The U.S. pharmaceutical CDMO market is growing thanks in large part to this strategic partnership and resource utilization, which also solidifies the company's position as a key link in the pharmaceutical industry's value chain.
Market Overview Growing need for end-to-end, fully integrated drug research and manufacturing solutions by biotechnology and pharmaceutical businesses is fueling the explosive growth of the U.S. pharmaceutical CDMO sector. A vast range of services are provided by contract development and manufacturing organizations (or CDMOs), such as supply chain management, quality assurance, product packaging, formulation development, regulatory support, clinical trial services, and knowledge transfer solutions. The growth of CDMOs into clinical research services through mergers, acquisitions, or the improvement of internal capabilities is a prominent trend in the sector. For businesses looking to outsource parts of medication research and manufacturing, this trend offers a lot of potential. It will cut costs, shorten time to market, and guarantee regulatory compliance. As the race to market new pharmaceuticals becomes more intense every year, CDMOs play a crucial role as strategic partners, offering comprehensive services that help pharmaceutical and biotechnology businesses every step of the way from discovery to commercialization. Businesses that have undergone this evolution include Vista Biologicals Corporation in California, which went from being a contract research and development organization to becoming a well-known Contract Development and Manufacturing Organization (CDMO).
Report Highlights By Product API category holds the greatest market share in the pharmaceutical contract development and manufacturing organization (CDMO) market in the United States. The primary components of pharmaceutical medicines, known as active pharmaceutical ingredients (APIs), are responsible for a large portion of their therapeutic efficacy. The range of capabilities that CDMOs provide for custom API manufacture includes physicochemical investigations, route scouting, optimization, purification, scale-up, and process development. . An obvious trend in the sector is the increased outsourcing of early- to late-stage API research and production projects that small- to large-scale biotech and pharmaceutical businesses have been observing. This highlights the critical role that CDMOs play in enabling the productive and efficient manufacture of APIs, satisfying the various demands of the pharmaceutical sector, and leveraging the advantages of outsourcing for increased adaptability and resource efficiency. In the forecast period, the drug segment is poised for substantial growth within the U.S. pharmaceutical contract development and manufacturing organization (CDMO) market. CDMOs play a crucial role in drug development by undertaking the initial phases of drug formulation and development before proceeding to manufacturing. This strategic outsourcing enables pharmaceutical companies to realize significant cost savings, time efficiencies, and resource optimization, as they no longer need to invest in building and staffing dedicated development and manufacturing facilities. By leveraging the expertise and infrastructure of CDMOs, pharmaceutical firms can streamline the drug development process, accelerate time to market, and focus on core competencies, driving innovation and market competitiveness. As the demand for outsourced drug development and manufacturing services continues to rise, the drug segment is poised to experience remarkable growth, reshaping the landscape of the pharmaceutical industry.
By Dosage Form With the greatest market size, Solid Dose emerges as the market leader in the pharmaceutical contract development and manufacturing organization (CDMO) sector in the United States. The foundation of the pharmaceutical industry, pharmaceutical solid dosage forms are extensively preferred by a wide range of patient demographics due to their effectiveness and convenience. Interestingly, pharmaceutical companies are devoting significant resources to the study and creation of more potent and palatable solid formulations. Because of the need to meet changing patient needs and pursue improved medication delivery strategies, the solid dose segment of the CDMO market is seeing increased traction. Over the course of the forecast period, Gaseous Dose is expected to have substantial expansion in the pharmaceutical contract development and manufacturing organization (CDMO) market in the United States. Therapeutically active medications are contained in these dosage forms, which are encased within containers and released upon the application of pressure. Gaseous dosage forms are mostly used for local administration into the mouth and nose or for topical application on the skin. They provide a variety of therapeutic delivery possibilities. They include medicinally active substances meant to be applied topically, injected into bodily cavities, or inhaled through the respiratory system. The growing requirement for gaseous dosage forms highlights their growing significance in pharmaceutical research with an emphasis on improving patient experience and efficacy. This presents CDMOs with profitable potential to broaden their service offerings and meet changing market demands.
By Indication During the course of the analysis, the U.S. pharmaceutical contract development and manufacturing organization (CDMO) industry is seeing a notable uptick in the pain indication category. Studies on the population, both domestically and internationally, show that those 65 years of age and older have a greater incidence of chronic pain than does the adult population as a whole. The most prevalent chronic pain problems affecting older persons are chronic nonspecific joint pain, chronic back pain, and chronic neck pain, with estimated prevalence rates ranging from 40% to 45% for joint pain, 5% to 45% for back pain, and 20% for neck pain. Older persons are more likely to experience chronic pain than younger adults, which puts a strain on healthcare systems and is linked to significant suffering, disability, and social isolation. The increasing awareness of the negative effects of chronic pain on quality of life highlights the need for pain management techniques, which is fueling the CDMO market's demand for contract development and manufacturing services customized to pain indication therapies. .
By End-Use In the pharmaceutical contract development and manufacturing organization (CDMO) market in the United States, the large pharmaceutical sector is the dominating market segment. By utilizing the knowledge of adaptable third-party service providers, CDMOs are essential to pharmaceutical businesses at every stage of the creation of drugs. Widely ranging from formulation and finishing processes to manufacturing and research and development, CDMOs provide end-to-end services customized to meet the demands of major pharmaceutical companies. By utilizing the specific capabilities of CDMOs, this strategic alliance enables pharmaceutical companies to maximize resources, improve efficiency, and concentrate on their core expertise. The partnership between large pharmaceutical companies and CDMOs is positioned to spur innovation, expedite the development of new products, and influence the direction of the pharmaceutical business as it continues to change. Over the course of the analysis period, the U.S. pharmaceutical contract development and manufacturing organization (CDMO) market is expected to witness stable expansion in the small and medium-sized pharmaceutical industry. The increasing need for biopharmaceuticals is what is driving this growth trajectory, and it has led to the formation of a specialized business model called the "contract development manufacturing organization (CDMO)" Small and medium-sized pharmaceutical businesses depend more and more on CDMOs to expedite the creation and execution of production processes. Small and medium-sized pharmaceutical companies can benefit from specialized infrastructure and experience by outsourcing these crucial parts to CDMOs, which in turn enables cost-effective and efficient drug development. The collaboration between small and medium-sized pharmaceutical businesses and CDMOs is expected to stimulate innovation and propel the pharmaceutical industry's growth, given the ongoing surge in demand for biopharmaceuticals.
Market Dynamics Driver Advancements in R&D and Quality Standards Focus on research and development (R&D) to create next-generation cGMP platforms for cell therapy, viral vectors, and plasmid DNA, together with Thermo Fisher Scientific's advanced therapeutic CDMO network, is a major factor driving the expansion of the pharmaceutical CDMO business in the United States. The superiority of cell therapy and viral vector CDMO services is further enhanced by the incorporation of advanced analytics to handle new regulatory trends and the application of best practices compliant with the most recent international quality and standards criteria. In addition to guaranteeing the delivery of premium pharmaceutical products, these strategic initiatives place CDMOs at the forefront of innovation and compliance in the ever-changing pharmaceutical industry. As a result of the quest of excellence in advanced therapeutic manufacturing and adherence to strict quality standards, the U.S. pharmaceutical CDMO industry experiencing fast growth.
Restraints Scale-Up Challenges and Volatile Volume Forecasts Constrain Unpredictable nature of product volume predictions and the difficulty of scale-up procedures present problems for the pharmaceutical CDMO business in the United States. Historically, CDMOs' accessible and unused manufacturing capacity has helped to minimize development delays and volatility in short-term volume predictions. But these limitations are now impeding commercial expansion. Operational challenges arise from inability to scale up production processes, and manufacturing planning and resource allocation are disrupted by imprecise or quickly changing volume projections. Consequently, the U.S. pharmaceutical CDMO market's potential for growth is limited by the inability to successfully address these issues, underscoring the urgent need for creative solutions to improve scalability and forecast accuracy in the pharmaceutical manufacturing
Opportunities Evolution of CDMOs as Technology Innovators With alliances with smaller startups and IT titans, CDMOs are well-positioned to expand their role as technological trailblazers and spur innovation in the pharmaceutical sector. To promote cooperation and ease the sharing of knowledge, major corporations are incorporating smaller startups and industry leaders in technology into their operations on a growing basis. It is anticipated that enterprises who prioritize their products will persist in their transition to the CDMO service sector, whilst CDMOs will broaden their range of products. . Integration of clinical trial services is a new trend that allows CDMOs to enter high-value, low-volume markets like customized medicine. However, this calls for a departure from the conventional volume-first strategy and a move toward a commercial model customized to the particular requirements of personalized care. Consumers increasingly expect CDMOs to offer knowledge across the whole manufacturing process, from manufacture to support during the commercial launch. The U.S. pharmaceutical CDMO market has a lot of opportunity to take advantage of this changing environment to grow its service offerings, leverage innovation, and adapt to the changing demands of the pharmaceutical business. . Recent Developments
• In November 2023, SOHM unveiled its new CDMO GMP manufacturing facility in Carlsbad, California. • In August 2022, Medipost acquired OmniaBio to launch its CDMO business in North America. • In January 2024, Alcami announced the acquisition of West-Coast based Pacific Pharmaceutical Services. • In March 2024, Lonza inked an agreement to acquire a large-scale biologics site in Vacaville (US) from Roche. • In July 2023, CVC Credit supported Biofarma Group’s acquisition of US Pharma Lab. • In May 2023, Baxter finalized a definitive agreement to divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 billion.
Key Players in the U.S. Pharmaceutical CDMO Market Bushu Pharmaceuticals Ltd. Nipro Corporation Thermo Fisher Scientific Inc. Samsung Biologics Laboratory Corporation of America Holdings Siegfried Holding Ag Catalent, Inc Lonza Group AG Recipharm Ab Piramal Pharma Solutions Cordenpharma International Cambrex Corporation Wuxi Apptec
Market Segmentation By Product API By Synthetic Solid Liquid By Type Traditional Active Pharmaceutical Ingredient (Traditional API) Highly Potent Active Pharmaceutical Ingredient (HP-API) Antibody Drug Conjugate (ADC) Others By Drug Innovative Generics By Manufacturing Continuous manufacturing Batch manufacturing Biotech By Drug Product Oral Solid Dose Semi-solid dose Liquid Dose Others
By Dosage Form Solid Tablets Capsules .Powder Semi-Solid Cream Paste Gel Liquid Dose Formulation Injectables Sterile Vials Single Use/Single Dose Multi-Use Ampules Prefilled Syringes Suspension Emulsion Gas Dose Formulation Inhaler Aerosols
By Indication Cancer Cardiovascular Disease Diabetes Pain Respiratory disease Other Disease
By End-User Big Pharmaceutical Companies Small & Medium-Sized Pharmaceutical Companies Generic Pharmaceutica
Table of content 1. Introduction 1.1. Report Description 1.2. Research Methodology 1.2.1. Data Mining 1.2.2. Market Modeling and Forecasting 1.2.3. Data Validation 1.2.4. Industry Analysis
4. U.S. Pharmaceutical CDMO Market by Product Type 4.1. Introduction 4.2. U.S. Pharmaceutical CDMO Market Size and Growth Rate by Product Type (2021-2030) 4.3. API 4.3.1. API Market Size and Growth Rate (2019- 2030)
5. U.S. Pharmaceutical CDMO Market by Synthetic 5.1. Introduction 5.2. U.S. Pharmaceutical CDMO Market Size and Growth Rate by Synthetic (2021-2030) 5.3. Solid 5.3.1. Solid Market Size and Growth Rate (2021-2030) 5.4, Liquid 5.4.1. Liquid Market Size and Growth Rate (2021-2030)
6. U.S. Pharmaceutical CDMO Market by Type 6.1. Introduction 6.2. U.S. Pharmaceutical CDMO Market Size and Growth Rate by Type (2021-2030) 6.3. Traditional Active Pharmaceutical Ingredient (Traditional API) 6.3.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Size and Growth Rate (2021-2030) 6.4, Highly Potent Active Pharmaceutical Ingredient (HP-API) 6.4.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Size and Growth Rate (2021-2030) 6.5, Antibody Drug Conjugate (ADC) 6.5.1. Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2021-2030) 6.6, Others 6.6.1. Others Market Size and Growth Rate (2021-2030)
7. U.S. Pharmaceutical CDMO Market by Drug 7.1. Introduction 7.2. U.S. Pharmaceutical CDMO Market Size and Growth Rate by Drug (2021-2030) 7.3. Innovative 7.3.1. Innovative Market Size and Growth Rate (2021-2030) 7.4, Generics 7.4.1. Generics Market Size and Growth Rate (2021-2030)
8. U.S. Pharmaceutical CDMO Market by Manufacturing 8.1. Introduction 8.2. U.S. Pharmaceutical CDMO Market Size and Growth Rate by Manufacturing (2021-2030) 8.3. Continuous manufacturing 8.3.1. Continuous manufacturing Market Size and Growth Rate (2021-2030) 8.4, Batch manufacturing 8.4.1. Batch manufacturing Market Size and Growth Rate (2021-2030) 8.4. Biotech 8.4.1. Biotech Market Size and Growth Rate (2021-2030)
9. U.S. Pharmaceutical CDMO Market by Drug Product 9.1. Introduction 9.2. U.S. Pharmaceutical CDMO Market Size and Growth Rate by Drug Product (2021-2030) 9.3. Oral Solid Dose 9.3.1. Oral Solid Dose Market Size and Growth Rate (2021-2030) 9.4, Oral Solid Dose 9.4.1. Oral Solid Dose Market Size and Growth Rate (2021-2030) 9.5. Liquid Dose 9.5.1. Liquid Dose Market Size and Growth Rate (2021-2030) 9.6, Others 9.6.1. Others Market Size and Growth Rate (2021-2030)
10. U.S. Pharmaceutical CDMO Market by Dosage Form 10.1. Introduction 10.2. U.S. Pharmaceutical CDMO Market Size and Growth Rate by Dosage Form (2021-2030) 10.3. Solid 10.3.1. Solid Market Size and Growth Rate (2021-2030) 10.4, Tablets 10.4.1. Tablets Market Size and Growth Rate (2021-2030) 10.5. Capsules 10.5.1. Capsules Market Size and Growth Rate (2021-2030) 10.6. Powder 10.6.1. Powder Market Size and Growth Rate (2021-2030) 10.13. Semi-Solid 10.13.1. Semi-Solid Market Size and Growth Rate (2021-2030) 10.8. Cream 10.8.1. Cream Market Size and Growth Rate (2021-2030) 10.9. Paste 10.9.1. Paste Market Size and Growth Rate (2021-2030) 10.10. Gel 10.10.1. Gel Market Size and Growth Rate (2021-2030) 10.11. Liquid Dose Formulation 10.11.1. Liquid Dose Formulation Market Size and Growth Rate (2021-2030) 10.12. Injectables 10.12.1. Injectables Market Size and Growth Rate (2021-2030) 10.13. Sterile Vials 10.13.1. Sterile Vials Market Size and Growth Rate (2021-2030) 10.14. Single Use/Single Dose 10.14.1. Single Use/Single Dose Market Size and Growth Rate (2021-2030) 10.15. Multi-Use 10.15.1. Multi-Use Market Size and Growth Rate (2021-2030) 10.16, Ampules 10.16.1. Ampules Market Size and Growth Rate (2021-2030) 10.113. Prefilled Syringes 10.113.1. Prefilled Syringes Market Size and Growth Rate (2021-2030) 10.18. Suspension 10.18.1. Suspension Market Size and Growth Rate (2021-2030) 10.19, Emulsion 10.19.1. Emulsion Market Size and Growth Rate (2021-2030) 10.20. Gas Dose Formulation 10.20.1. Gas Dose Formulation Market Size and Growth Rate (2021-2030) 10.21. Inhaler 10.21.1. Inhaler Market Size and Growth Rate (2021-2030) 10.22, Aerosols 10.22.1. Aerosols Market Size and Growth Rate (2021-2030)
11. U.S. Pharmaceutical CDMO Market by Indication 11.1. Introduction 11.2. U.S. Pharmaceutical CDMO Market Size and Growth Rate by Therapeutic Area (2021-2030) 11.3. Cancer 11.3.1. Cancer Market Size and Growth Rate (2021-2030) 11.4, Cardiovascular Disease 11.4.1. Cardiovascular Disease Market Size and Growth Rate (2021-2030) 11.5. Diabetes 11.5.1. Diabetes Market Size and Growth Rate (2021-2030) 11.6. Pain 11.6.1. Pain Market Size and Growth Rate (2021-2030) 11.13. Respiratory disease 11.13.1. Respiratory disease Market Size and Growth Rate (2021-2030) 11.8. Other Disease 11.8.1. Other Disease Market Size and Growth Rate (2021-2030)
12. U.S. Pharmaceutical CDMO Market by End-User 12.1. Introduction 12.2. U.S. Pharmaceutical CDMO Market Size and Growth Rate by End-User (2021-2030) 12.3. Big Pharmaceutical Companies 12.3.1. Big Pharmaceutical Companies Market Size and Growth Rate (2021-2030) 12.4, Small & Medium-Sized Pharmaceutical Companies 12.4.1. Small & Medium-Sized Pharmaceutical Companies Market Size and Growth Rate (2021-2030) 12.5. Generic Pharmaceutical 12.5.1. Generic Pharmaceutical Market Size and Growth Rate (2021-2030)
13. Company Profiles 13.1. Bushu Pharmaceuticals Ltd. 13.1.1. Business Overview 13.1.2. Service Portfolio 13.1.3. Strategic Developments 13.1.4. Financial Overview
13.2 Nipro Corporation 13.2.1. Business Overview 13.2.2. Service Portfolio 13.2.3. Strategic Developments 13.2.4. Financial Overview
13.3. Thermo Fisher Scientific Inc. 13.3.1. Business Overview 13.3.2. Service Portfolio 13.3.3. Strategic Developments 13.3.4. Financial Overview
13.4. Samsung Biologics 13.4.1. Business Overview 13.4.2. Service Portfolio 13.4.3. Strategic Developments 13.4.4. Financial Overview
13.4. Laboratory Corporation of America Holdings 13.4.1. Business Overview 13.4.2. Service Portfolio 13.4.3. Strategic Developments 13.4.4. Financial Overview
13.4. Siegfried Holding Ag 13.4.1. Business Overview 13.4.2. Service Portfolio 13.4.3. Strategic Developments 13.4.4. Financial Overview
13.4. Catalent, Inc 13.4.1. Business Overview 13.4.2. Service Portfolio 13.4.3. Strategic Developments 13.4.4. Financial Overview
13.4. Lonza Group AG. 13.4.1. Business Overview 13.4.2. Service Portfolio 13.4.3. Strategic Developments 13.4.4. Financial Overview
13.4. Recipharm Ab. 13.4.1. Business Overview 13.4.2. Service Portfolio 13.4.3. Strategic Developments 13.4.4. Financial Overview
13.4. Piramal Pharma Solutions. 13.4.1. Business Overview 13.4.2. Service Portfolio 13.4.3. Strategic Developments 13.4.4. Financial Overview
13.4. Cordenpharma International 13.4.1. Business Overview 13.4.2. Service Portfolio 13.4.3. Strategic Developments 13.4.4. Financial Overview
13.4. Cambrex Corporation. 13.4.1. Business Overview 13.4.2. Service Portfolio 13.4.3. Strategic Developments 13.4.4. Financial Overview
13.4 Wuxi Apptec 13.4.1. Business Overview 13.4.2. Service Portfolio 13.4.3. Strategic Developments 13.4.4. Financial Overview
14. List of Tables and Figures Table U.S. Pharmaceutical CDMO Market Size and Market Share by Product Type (2021-2023) Table U.S. Pharmaceutical CDMO Market Size and Market Share by Product Type (2023-2030) Figure API Market Size and Growth Rate (2021-2030)
Table U.S. Pharmaceutical CDMO Market Size and Market Share by Synthetic Type (2021-2023) Table U.S. Pharmaceutical CDMO Market Size and Market Share by Product Type (2023-2030) Figure Solid Market Size and Growth Rate (2021-2030) Figure Liquid Market Size and Growth Rate (2021-2030)
Table U.S. Pharmaceutical CDMO Market Size and Market Share by Type (2021-2023) Table U.S. Pharmaceutical CDMO Market Size and Market Share by Product Type (2023-2030) Figure Traditional Active Pharmaceutical Ingredient (Traditional API) Market Size and Growth Rate (2021-2030) Figure Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Size and Growth Rate (2021-2030) Figure Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2021-2030) Figure Others Market Size and Growth Rate (2021-2030)
Table U.S. Pharmaceutical CDMO Market Size and Market Share by DrugType (2021-2023) Table U.S. Pharmaceutical CDMO Market Size and Market Share by Product Type (2023-2030) Figure Innovative Market Size and Growth Rate (2021-2030) Figure Generics Market Size and Growth Rate (2021-2030)
Table U.S. Pharmaceutical CDMO Market Size and Market Share by Manufacturing Type (2021-2023) Table U.S. Pharmaceutical CDMO Market Size and Market Share by Product Type (2023-2030) Figure Continuous manufacturing Market Size and Growth Rate (2021-2030) Figure Batch manufacturing Market Size and Growth Rate (2021-2030) Figure Others Market Size and Growth Rate (2021-2030) Table U.S. Pharmaceutical CDMO Market Size and Market Share by Drug Product Type (2021-2023) Table U.S. Pharmaceutical CDMO Market Size and Market Share by Product Type (2023-2030) Figure Oral Solid Dose Market Size and Growth Rate (2021-2030) Figure Semi-solid dose Market Size and Growth Rate (2021-2030) Figure Liquid Dose Market Size and Growth Rate (2021-2030) Figure Others Market Size and Growth Rate (2021-2030) Table U.S. Pharmaceutical CDMO Market Size and Market Share by Dosage Form Type (2021-2023) Table U.S. Pharmaceutical CDMO Market Size and Market Share by Product Type (2023-2030) Figure Solid Market Size and Growth Rate (2021-2030) Figure Tablets Market Size and Growth Rate (2021-2030) Figure Capsules Market Size and Growth Rate (2021-2030) Figure Powder Market Size and Growth Rate (2021-2030) Figure Semi-Solid Market Size and Growth Rate (2021-2030) Figure Cream Market Size and Growth Rate (2021-2030) Figure Paste Market Size and Growth Rate (2021-2030) Figure Gel Market Size and Growth Rate (2021-2030) Figure Liquid Dose Formulation Market Size and Growth Rate (2021-2030) Figure Injectables Market Size and Growth Rate (2021-2030) Figure Sterile Vials Market Size and Growth Rate (2021-2030) Figure Single Use/Single Dose Market Size and Growth Rate (2021-2030) Figure Multi-Use Market Size and Growth Rate (2021-2030)
Figure Ampules Market Size and Growth Rate (2021-2030) Figure Prefilled Syringes Market Size and Growth Rate (2021-2030) Figure Suspension Market Size and Growth Rate (2021-2030) Figure Emulsion Market Size and Growth Rate (2021-2030) Figure Gas Dose Formulation Market Size and Growth Rate (2021-2030) Figure Inhaler Market Size and Growth Rate (2021-2030) Figure Aerosols Market Size and Growth Rate (2021-2030)
Table U.S. Pharmaceutical CDMO Market Size and Market Share by Indication Type (2021-2023) Table U.S. Pharmaceutical CDMO Market Size and Market Share by Therapeutic Area Type (2023-2030) Figure Cancer Market Size and Growth Rate (2021-2030) Figure Cardiovascular Disease Market Size and Growth Rate (2021-2030) Figure DiabetesMarket Size and Growth Rate (2021-2030) Figure Pain Market Size and Growth Rate (2021-2030) Figure Respiratory disease Market Size and Growth Rate (2021-2030) Figure Other Disease Market Size and Growth Rate (2021-2030)
Table U.S. Pharmaceutical CDMO Market Size and Market Share by End-User Type (2021-2023) Table U.S. Pharmaceutical CDMO Market Size and Market Share by Therapeutic Area Type (2023-2030) Figure Big Pharmaceutical Companies Market Size and Growth Rate (2021-2030) Figure Small & Medium-Sized Pharmaceutical Companies Market Size and Growth Rate (2021-2030) Figure Generic Pharmaceutical Market Size and Growth Rate (2021-2030)
Table U.S. Pharmaceutical CDMO Market by Regions (2023-2030)
Table U.S. Pharmaceutical CDMO Market by Product Type (2021-2023) Table U.S. Pharmaceutical CDMO Market by Product Type (2023-2030) Table U.S. Pharmaceutical CDMO by Synthetic (2021-2023) Table U.S. Pharmaceutical CDMO by Synthetic (2023-2030) Table U.S. Pharmaceutical CDMO by Type (2021-2023) Table U.S. Pharmaceutical CDMO by Type (2023-2030) Table U.S. Pharmaceutical CDMO by Drug (2021-2023) Table U.S. Pharmaceutical CDMO by Drug (2023-2030) Table U.S. Pharmaceutical CDMO by Manufacturing (2021-2023) Table U.S. Pharmaceutical CDMO by Manufacturing (2023-2030) Table U.S. Pharmaceutical CDMO by Drug Product (2021-2023) Table U.S. Pharmaceutical CDMO by Drug Product (2023-2030) Table U.S. Pharmaceutical CDMO by Indication (2021-2023) Table U.S. Pharmaceutical CDMO by Indication (2023-2030) Table U.S. Pharmaceutical CDMO by End-User (2021-2023) Table U.S. Pharmaceutical CDMO by End-User (2023-2030)
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of U.S. Pharmaceutical CDMO and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of U.S. Pharmaceutical CDMO Market for the past year and forecasts for the next six years. U.S. Pharmaceutical CDMO Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different U.S. Pharmaceutical CDMO Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for U.S. Pharmaceutical CDMO from different application industries in different regions.
Market Segmentation By Product API By Synthetic Solid Liquid By Type Traditional Active Pharmaceutical Ingredient (Traditional API) Highly Potent Active Pharmaceutical Ingredient (HP-API) Antibody Drug Conjugate (ADC) Others By Drug Innovative Generics By Manufacturing Continuous manufacturing Batch manufacturing Biotech By Drug Product Oral Solid Dose Semi-solid dose Liquid Dose Others
By Dosage Form Solid Tablets Capsules .Powder Semi-Solid Cream Paste Gel Liquid Dose Formulation Injectables Sterile Vials Single Use/Single Dose Multi-Use Ampules Prefilled Syringes Suspension Emulsion Gas Dose Formulation Inhaler Aerosols
By Indication Cancer Cardiovascular Disease Diabetes Pain Respiratory disease Other Disease
By End-User Big Pharmaceutical Companies Small & Medium-Sized Pharmaceutical Companies Generic Pharmaceutica
